Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W P Bowman

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Journal of the National Cancer Institute|February 19, 1992
Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemiaN J Winick, W P Bowman, B A Kamen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1983
Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone, and vincristineC H Pui, C W Jackson, C Chesney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemiaN Winick, J J Shuster, W P Bowman, et al.
Lancet (London, England)|February 18, 1984
Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemiaW E Evans, W R Crom, C F Stewart, et al.
Clinical Pharmacology and Therapeutics|March 1, 1983
Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusionW E Evans, P R Hutson, C F Stewart, et al.
Cancer Research|July 1, 1981
Clinical utility of initial terminal deoxynucleotidyl transferase determinations in childhood acute leukemiasD K Kalwinsky, W H Weatherred, G V Dahl, et al.
Drug Intelligence & Clinical Pharmacy|November 1, 1982
Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemiaW E Evans, C F Stewart, P R Hutson, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemiaW E Evans, M Abromowitch, W R Crom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1983
Second central nervous system prophylaxis in children with acute lymphoblastic leukemia who relapse after elective cessation of therapyG Rivera, S L George, W P Bowman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1986
Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabineS B Murphy, W P Bowman, M Abromowitch, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Journal of the National Cancer Institute|February 19, 1992
Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemiaN J Winick, W P Bowman, B A Kamen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1983
Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone, and vincristineC H Pui, C W Jackson, C Chesney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemiaN Winick, J J Shuster, W P Bowman, et al.
Lancet (London, England)|February 18, 1984
Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemiaW E Evans, W R Crom, C F Stewart, et al.
Clinical Pharmacology and Therapeutics|March 1, 1983
Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusionW E Evans, P R Hutson, C F Stewart, et al.
Cancer Research|July 1, 1981
Clinical utility of initial terminal deoxynucleotidyl transferase determinations in childhood acute leukemiasD K Kalwinsky, W H Weatherred, G V Dahl, et al.
Drug Intelligence & Clinical Pharmacy|November 1, 1982
Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemiaW E Evans, C F Stewart, P R Hutson, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemiaW E Evans, M Abromowitch, W R Crom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1983
Second central nervous system prophylaxis in children with acute lymphoblastic leukemia who relapse after elective cessation of therapyG Rivera, S L George, W P Bowman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1986
Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabineS B Murphy, W P Bowman, M Abromowitch, et al.
Pageof 7